Fabrication of Mesoporous Manganese Nanoparticles Incorporated Aβ‐Peptide Inhibits Aβ Aggregation and Alleviates Neuroinflammation Against Alzheimer's Disease
Journal of Biomedical Materials Research Part B: Applied Biomaterials · 2026
DOI: 10.1002/jbm.b.70131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2026. Verfasst von Haipeng Lu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jin Hua, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Manganese, Nanoparticles. Die Arbeit nennt 51 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Extracellular amyloid plaques from Aβ accumulation and intracellular neurofibrillary tangles (NFTs) from hyperphosphorylated Tau (p‐Tau), both leading to neuronal dysfunction, synapse loss, and cognitive decline. Nonetheless, achieving an effective therapeutic outcome is challenging due to the limited drug bioavailability through the blood–brain barrier (BBB) and the complex microenvironment within the brain. This study proposes MM‐TA for the synergistic treatment of AD, utilizing mesoporous manganese (MM) as a nanocarrier to deliver a LK7 (Aβ‐inhibiting peptide) and a DAA (amino acid‐peptide) that inhibits Tau‐related fibrils formation. A biomimetic nanocarrier (MM‐LD@4CM termed as MLDC) encapsulated with 4T1 cell membranes (4CM) was developed, inspired by 4T1 cells' ability to facilitate BBB penetration. Following traversal of the BBB, MLDC concurrently prevented Tau phosphorylation and suppressed Aβ aggregation. Furthermore, by leveraging MM's catalase‐mimetic properties, MLDC mitigated oxidative stress and altered the microenvironment associated with AD progression. In contrast to the singular therapeutic agent, MLDC ameliorated nerve damage and enhanced cognitive function in AD mice by reducing Aβ oligomers, phosphorylated Tau, and inflammation, thereby providing a synergistic therapeutic approach with significant potential for effective AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jin Hua, China.
ORCID-Profile: Yaming Fu
Zitieren
APA
Lu, H., Hu, C., & Fu, Y. (2026). Fabrication of Mesoporous Manganese Nanoparticles Incorporated Aβ‐Peptide Inhibits Aβ Aggregation and Alleviates Neuroinflammation Against Alzheimer's Disease. Journal of Biomedical Materials Research Part B: Applied Biomaterials. https://doi.org/10.1002/jbm.b.70131
Vancouver
Lu H, Hu C, Fu Y. Fabrication of Mesoporous Manganese Nanoparticles Incorporated Aβ‐Peptide Inhibits Aβ Aggregation and Alleviates Neuroinflammation Against Alzheimer's Disease. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2026. doi:10.1002/jbm.b.70131
BibTeX
@article{Lu2026,
author = {Lu, Haipeng and Hu, Chuanchen and Fu, Yaming},
title = {Fabrication of Mesoporous Manganese Nanoparticles Incorporated Aβ‐Peptide Inhibits Aβ Aggregation and Alleviates Neuroinflammation Against Alzheimer's Disease},
journal = {Journal of Biomedical Materials Research Part B: Applied Biomaterials},
year = {2026},
doi = {10.1002/jbm.b.70131}
}
EUVIMED